Noom has launched Proactive Health Microdose GLP-1 Rx, positioning the program as a preventive health offering rather than a weight loss solution. The program costs $149 per month and is available to individuals with a BMI of 21 or higher.
“Today marks the start of a new era for Noom,” said CEO Geoff Cook. “Now, we can intervene sooner. We can get in front of chronic disease and reach people before metabolic disorder takes root.”
The program combines low-dose GLP-1 medication with at-home biomarker testing and Noom’s digital behavior change platform. The blood test, delivered every four months, tracks 17 biomarkers including HbA1c, ApoB, hs-CRP, and hormonal markers such as DHEA-S, testosterone, and estradiol.
“The problem we’re solving is that most Americans are living with suboptimal health — and their blood biomarkers show it,” said Dr. Jeffrey Egler, Chief Medical Officer at Noom. “Roughly three in four adults in midlife are living with at least one chronic health condition.”
Noom first introduced its Microdose GLP-1 Program in August for people with a BMI of 25 or higher. The new program’s starting dose is 25% of the lowest starting dose in Noom’s other GLP-1 offerings.
The company cites estimates that up to 92% of people eventually stop taking GLP-1 medications. Noom reports that members in the top quartile of engagement on its platform lose 50% more weight on average than those in the bottom quartile after eight weeks.
The program is available to eligible members in the United States.
